PA-BOOMI
13.7.2022 15:22:14 CEST | Business Wire | Press release
Boomi™ , the intelligent connectivity and automation leader, today announced the recipients of its 2022 EMEA Partner awards, who were formally honored at Boomi’s recent EMEA Partner Summit in Amsterdam. The event brought together more than 300 attendees from Boomi partners from across the region to learn, network, and share best practices. It was also an opportunity for Boomi to recognize its partners for their innovative work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005287/en/
“Our partners are trusted advisors, strategic consultants, leaders in IT and digital transformation, and innovators in the cloud infrastructure space,” said Derek Thompson, Vice President of Business Development, EMEA at Boomi. “They solve problems and proactively implement Boomi’s technology day in and day out. We’re honored to recognize the work they accomplished this past year.”
“As organizations face significant challenges to transform their business to achieve the strategic and operational objectives, enterprise integration is on top of the agenda for CIOs and CDOs,” said Jason Newman, Partner, Integration Services, Deloitte UK. “We are very proud of the work we do to consistently deliver innovative solutions to solve complex business challenges for our clients. This award is a strong testament to the highly skilled and talented people we have in the Deloitte Integration Services team and the strong partnership with Boomi.”
This year’s winners of the EMEA Partner Summit Awards include:
Innovative Project of the Year
- Global Systems Integrator (GSI): Accenture
- Systems Integrator (SI): IntegrationWorks GmbH
Solution Partner of the Year
- Global Systems Integrator (GSI): Deloitte
- Systems Integrator (SI): Cegeka
Individual Contributor Award: Mukesh Gehlot, CEO, NeosAlpha
- Highly Commended:
- Isto Kaitosaari, CTO, Integrations Group
- Guillaume Rozier, Associate Partner, Fekra
Sales and Marketing Campaign of the Year: Gambit
Services Partner Of The Year: Viseo
-
Highly Commended:
- B-Flow
- Onepoint Consulting
Emerging Markets Partner of the Year: Xitricon
Rising Star: Syscons
“As a Boomi partner, we appreciate the recognition,” said Mukesh Gehlot, CEO, NeosAlpha. “Boomi’s commitment to its partners, as well as customer success, goes above and beyond.”
Boomi recently expanded its Partner Resource Center , which provides insightful content as well as opportunities for partners to further promote their brand and value proposition to end-users through the Partner Finder. Additionally, Boomi simplified program requirements and the way partners do business by providing a clear partner onboarding path and streamlining partner training for accreditations and certifications.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Enterprise Integration Platform as a Service (EiPaaS) for eight consecutive years .
As a category-leading, global software as a service (SaaS) company with more than 20,000 customers – Boomi touts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSIs) in the iPaaS space, which includes Accenture, Deloitte, SAP, and Snowflake, as well as the three largest cloud providers, Amazon Web Services, Google, and Microsoft, among others.
The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered a prestigious 5-star rating in the CRN Partner Program Guide, a definitive list of the most notable partner programs from industry-leading technology vendors that provide innovative products and flexible services through the IT channel. Boomi’s cloud-native, low-code platform helps organizations across all industries connect data applications, streamline workflows, and deliver more integrated customer experiences.
To learn more about partnering with Boomi or to find a partner from Boomi’s global ecosystem, visit https://boomi.com/partners/ .
Additional Resources
- Learn more about Boomi's Partner Program
- Read the blog post Why Connections Matter to Partners
- Learn more about The Boomi AtomSphere Platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter , LinkedIn , Facebook , and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com
.
© 2022 Boomi, LP. Boomi, the ‘B’ logo, Boomiverse, and AtomSphere are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005287/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom